Your browser is no longer supported. Please, upgrade your browser.
Settings
CASI CASI Pharmaceuticals, Inc. daily Stock Chart
CASI [NASD]
CASI Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own0.70% Shs Outstand97.84M Perf Week1.55%
Market Cap320.92M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float57.63M Perf Month-0.91%
Income-27.50M PEG- EPS next Q-0.09 Inst Own21.10% Short Float8.01% Perf Quarter-9.39%
Sales- P/S- EPS this Y-85.10% Inst Trans0.34% Short Ratio25.05 Perf Half Y-6.82%
Book/sh1.09 P/B3.01 EPS next Y40.70% ROA-28.30% Target Price7.00 Perf Year-54.51%
Cash/sh1.03 P/C3.19 EPS next 5Y- ROE-31.20% 52W Range2.73 - 8.89 Perf YTD-18.41%
Dividend- P/FCF- EPS past 5Y-8.10% ROI- 52W High-63.11% Beta1.24
Dividend %- Quick Ratio21.50 Sales past 5Y- Gross Margin- 52W Low20.15% ATR0.14
Employees124 Current Ratio21.50 Sales Q/Q- Oper. Margin- RSI (14)51.75 Volatility3.24% 4.18%
OptionableNo Debt/Eq0.01 EPS Q/Q-69.50% Profit Margin- Rel Volume0.38 Prev Close3.15
ShortableYes LT Debt/Eq0.00 EarningsApr 11 BMO Payout- Avg Volume184.15K Price3.28
Recom- SMA20-0.17% SMA501.50% SMA200-22.08% Volume70,003 Change4.13%
Sep-22-16Initiated Maxim Group Buy $4
Oct-29-15Resumed H.C. Wainwright Buy $2.50 → $3
Jun-23-15Initiated H.C. Wainwright Buy $2.50
May-20-19 09:45AM  CASI: Making headway towards commercialization Zacks Small Cap Research
May-15-19 07:00AM  CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results PR Newswire
May-13-19 10:00AM  CASI: Initiating coverage Leveraging pharmaceutical opportunities in China and beyond Zacks Small Cap Research -5.36%
May-03-19 08:42AM  Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down Zacks
Apr-18-19 04:15PM  INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers PR Newswire
Apr-17-19 07:00AM  CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics PR Newswire
Apr-02-19 07:00AM  CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer PR Newswire -5.00%
Mar-29-19 07:00AM  CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results PR Newswire -9.46%
Mar-13-19 07:00AM  CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China PR Newswire
Mar-07-19 07:00AM  CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO® PR Newswire
Feb-26-19 08:14AM  When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit? Simply Wall St.
Feb-20-19 08:15AM  Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett Future Expectations, Projections Moving into 2019 GlobeNewswire
Feb-19-19 07:00AM  CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN® PR Newswire
Feb-06-19 07:00AM  CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference PR Newswire
Dec-28-18 11:45AM  These 4 Healthcare Stocks Are Heating Up ACCESSWIRE
Dec-26-18 09:32AM  Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)? Simply Wall St. +7.23%
Dec-03-18 09:15AM  The 4 Healthcare Stocks To Watch On Monday ACCESSWIRE +5.31%
08:12AM  CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®) PR Newswire
Nov-30-18 04:05PM  Chinese biotech stocks hit by a double whammy, which means its time to buy MarketWatch +10.74%
Nov-28-18 08:40AM  Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-16-18 07:00AM  CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China PR Newswire +16.48%
Nov-14-18 07:00AM  CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results PR Newswire
Oct-24-18 08:00AM  Todays Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences ACCESSWIRE -15.63%
Oct-23-18 03:47PM  Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today Motley Fool +20.96%
02:30PM  3 Healthcare Stocks Trending Higher On News ACCESSWIRE
07:05AM  CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited PR Newswire
Oct-18-18 08:40AM  Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-02-18 07:00AM  CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization PR Newswire
Sep-28-18 07:00AM  CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer PR Newswire -9.50%
Sep-14-18 07:00AM  CASI Pharmaceuticals Announces $48.5 Million Private Placement PR Newswire
Aug-27-18 08:20AM  Factors of Influence in 2018, Key Indicators and Opportunity within Steelcase, SecureWorks, Cleveland-Cliffs, Tredegar, Warrior Met Coal, and CASI Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Aug-14-18 07:00AM  CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results PR Newswire
Jul-05-18 07:43AM  Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index Benzinga
Jul-03-18 01:05PM  CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes PR Newswire
Jun-25-18 08:00AM  Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals, Peabody Energy, Alcoa, and Edwards Lifesciences New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-21-18 04:14PM  Here's Why CASI Pharmaceuticals Rose as Much as 31.6% Today Motley Fool
07:00AM  CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol PR Newswire
May-31-18 08:30AM  Free Technical Insights on CASI Pharma and Three Other Biotech Stocks ACCESSWIRE -5.65%
May-29-18 07:00AM  CASI Pharmaceuticals To Present At The BIO International Convention PR Newswire -5.89%
May-15-18 07:00AM  CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results PR Newswire
May-07-18 07:30AM  Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch +11.62%
Apr-30-18 04:47PM  Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool
Apr-16-18 07:40AM  Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH ACCESSWIRE
Apr-08-18 07:17AM  What Stocks Perform Well in the Midst of a Trade War? Motley Fool
Apr-06-18 04:23PM  Here's Why CASI Pharmaceuticals Rose as Much as 23.4% Today Motley Fool +13.98%
Apr-05-18 08:00AM  CASI Pharmaceuticals Provides Update On EVOMELA® PR Newswire
Apr-03-18 07:00AM  CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference PR Newswire +47.54%
Mar-29-18 07:00AM  CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results PR Newswire +9.45%
Mar-21-18 08:10AM  Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals ACCESSWIRE
Mar-20-18 09:29AM  CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China PR Newswire +21.81%
Mar-05-18 08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Cypress Semiconductor, Abaxis,Inc, Universal Health Services, CASI Pharmaceuticals, Energy Transfer Partners, and Arconic New Research Emphasizes Economic Growth GlobeNewswire
Feb-09-18 07:00AM  CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference PR Newswire
Jan-30-18 07:50AM  Wired News CASI Pharma Purchased abbreviated new drug applications Portfolio from Sandoz ACCESSWIRE
Jan-26-18 05:00PM  CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz) PR Newswire
Dec-01-17 07:00AM  CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC) PR Newswire +18.24%
Nov-14-17 07:00AM  CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results PR Newswire +8.37%
Nov-02-17 08:15AM  Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-31-17 07:30AM  CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance ACCESSWIRE
Oct-13-17 10:00AM  CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders PR Newswire -25.27%
Sep-07-17 07:00AM  CASI Provides Pipeline Development Update PR Newswire +5.77%
Sep-06-17 07:00AM  CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference PR Newswire
Aug-14-17 07:00AM  CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results PR Newswire
May-30-17 07:00AM  CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma (CCOC) PR Newswire
May-18-17 07:00AM  CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer PR Newswire
May-15-17 07:00AM  CASI Pharmaceuticals Reports First Quarter 2017 Financial Results PR Newswire
Apr-14-17 07:00AM  CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer PR Newswire
Apr-04-17 01:00PM  CASI Exited Fiscal 2016 with a Strong Balance Sheet Zacks Small Cap Research
01:00PM  CASI Exited Fiscal 2016 with a Strong Balance Sheet
Mar-31-17 09:02AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:00AM  CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results PR Newswire
Mar-28-17 07:00AM  CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting PR Newswire
Dec-16-16 04:33PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Dec-05-16 11:35AM  CASI Pharmaceuticals, Inc. :CASI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
07:00AM  CASI Pharmaceuticals' Import Drug Registration Application For EVOMELA® Accepted For Review By CFDA PR Newswire
Nov-19-16 01:04PM  CASI PHARMACEUTICALS, INC. Financials
Nov-14-16 09:04AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:00AM  CASI Pharmaceuticals Reports Third Quarter 2016 Financial Results PR Newswire
Oct-25-16 04:31PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
Oct-05-16 05:07PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Sep-22-16 05:49AM  Coverage initiated on CASI Pharma by Maxim Group
Aug-16-16 07:00AM  CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma PR Newswire
Aug-15-16 09:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:00AM  CASI Pharmaceuticals Reports Second Quarter 2016 Financial Results PR Newswire
Jun-27-16 04:47PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Jun-13-16 11:18AM  CASI: Company Announces Positive Phase II Data on ENMD-2076 in Patients with OCCC At ASCO Zacks Small Cap Research
11:18AM  CASI: Company Announces Positive Phase II Data on ENMD-2076 in Patients with OCCC At ASCO
Jun-03-16 04:47PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
Jun-01-16 07:00AM  CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC) PR Newswire
May-13-16 09:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:00AM  CASI Pharmaceuticals Reports First Quarter 2016 Financial Results PR Newswire
May-12-16 07:00AM  CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) PR Newswire
Apr-18-16 07:00AM  James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development PR Newswire
Mar-31-16 08:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Mar-30-16 11:51AM  CASI Pharmaceuticals, Inc. :CASI-US: Earnings Analysis: 2015 By the Numbers
Mar-28-16 09:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:29AM  CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results at noodls
07:00AM  CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results PR Newswire
Mar-18-16 04:33PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Feb-17-16 04:32PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hu Cynthia W.COO, Gen Counsel & SecretaryJan 14Option Exercise1.7615,00026,40032,785Jan 15 04:02 PM
CAPITELLI SARA BVP Fin & Principal Account OffJul 12Option Exercise1.9935,00069,47535,000Jul 13 05:09 PM